Age distribution, tobacco smoke habit and DNA ploidy status in oral potentially malignant disordes (OPMDs) and oral squamous cell carcinomas (OSCCs) patients.

<p>The bottom and the top of each box show the first and third quartile while the line inside the box represents the median (second quartile). The tips of the whiskers represent the minimum and the maximum data value. The number of patients for each category is indicated at the bottom of the corresponding box. The boxes corresponding to DNA diploid OPMDs/OSCCs are white while those corresponding to DNA aneuploid OPMDs/OSCCs have a striped pattern. Significant (MW test) P-values (P < 0.05) are indicated. The FDR q-value method was applied for multiple testing (n = 8) correction and the resulting q-values are indicated.</p

Patients’ characteristics and differences in age distribution among patient subgroups.

<p>Patients’ characteristics and differences in age distribution among patient subgroups.</p

Relationship between ploidy status, age, and smoke habit, in OPMDs^a and OSCCs^b patients.

<p>Relationship between ploidy status, age, and smoke habit, in OPMDs<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0184425#t004fn001" target="_blank">^a</a> and OSCCs<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0184425#t004fn002" target="_blank">^b</a> patients.</p

Mean number of genomic aberrations (MNGA) per patient and age or smoking status in oral potentially malignant disordes (OPMDs) and oral squamous cell carcinomas (OSCCs) patients.

<p>The average number of aberrations per patient is represented as gray dots superimposed over boxes. These present a thick horizontal line indicating the median number per group, and delimitate the 25^th and 75^th percentile, while whiskers show the 95% confidence interval. A) average number of aberrations per patients’ age; B) average number of aberrations per patients’ smoking habit.</p

Patients’ tobacco consumption details (54 former and 76 current smokers).

<p>Patients’ tobacco consumption details (54 former and 76 current smokers).</p

NAC, Tiron and Trolox Impair Survival of Cell Cultures Containing Glioblastoma Tumorigenic Initiating Cells by Inhibition of Cell Cycle Progression

<div><p>Reactive oxygen species (ROS) are metabolism by-products that may act as signaling molecules to sustain tumor growth. Antioxidants have been used to impair cancer cell survival. Our goal was to determine the mechanisms involved in the response to antioxidants of a human cell culture (PT4) containing glioblastoma (GBM) tumorigenic initiating cells (TICs). ROS production in the absence or presence of N-acetyl-L-cysteine (NAC), tiron, and trolox was evaluated by flow cytometry (FCM). The effects of these antioxidants on cell survival and apoptosis were evaluated by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT) and FCM. The biological processes modulated by these drugs were determined by oligonucleotide microarray gene expression profiling. Our results showed that NAC, tiron and trolox impaired PT4 cell survival, had minor effects on ROS levels and caused wide deregulation of cell cycle genes. Furthermore, tiron and trolox caused inhibition of cell survival in two additional cell cultures containing TICs, FO-1 and MM1, established from a melanoma and a mesothelioma patient, respectively. NAC, instead, impaired survival of the MM1 cells but not of the FO-1 cells. However, when used in combination, NAC enhanced the inhibitory effect of PLX4032 (BRAF V600E inhibitor) and Gefitinib (EGFR inhibitor), on FO-1 and PT4 cell survival. Collectively, NAC, tiron and trolox modulated gene expression and impaired the growth of cultures containing TICs primarily by inhibiting cell cycle progression.</p></div

Validation of gene expression regulation by Real-time RT-PCR and Immunoblot analysis.

<p>(A) Real-Time RT-PCR analysis performed with RNA extracted from the PT4 cell culture containing GBM TICs to validate the microarray data. This was accomplished on randomly selected genes from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0090085#pone.0090085.s012" target="_blank">Table S3</a> and showed, in arbitrary units. Expression levels are relative to the expression of the housekeeping gene transcript coding for the ribosomal protein L19 (RPL19). Standard deviations are indicated as vertical bars (n = 3 independent assays). Gene name symbols are those approved by the Human Genome Organization Gene Nomenclature Committee (<a href="http://www.genenames.org/" target="_blank">http://www.genenames.org/</a>). Standard deviations are indicated as vertical bars (n = 3 independent assays). #The unpaired t-test was significant at P<0.05. §The unpaired t-test was significant at P<0.01. *The unpaired t-test was significant at P<0.001. (B) Western blot analyses were performed with lysates of the PT4 cell culture containing GBM TICs treated for 48 h with the indicated antioxidant drug and challenged with anti MKi67, Pdz-binding kinase (PBK), transferrin receptor (TFRC), carbonic anhydrase 9 (CA9). (C) Western blot analyses were performed with lysates of the PT4 cell culture containing GBM TICs treated for 6 days with the indicated antioxidant drug and challenged with anti nestin (NES), oligodendrocyte transcription factor 2 (OLIG2), SRY (sex determining region Y)-box 2 (SOX2) and tumor protein 53 (TP53) antibodies. (D) Western blot analyses were performed with lysates of the PT4 cell culture containing GBM TICs treated for 48 h with the indicated antioxidant drug and challenged with anti tumor protein 53 (TP53) mAb. (B–D) Immunoblotted membranes were subjected to multiple antibody challenging, stripping, control of effective stripping, and re-challenging with a different antibody. The last antibody used was an anti histone deacetylase 1 (HDAC1) (B) or an anti tubulin alpha (D) to show equal loading.</p

Cell survival of the PT4, MM1 and FO-1 cell cultures containing TICs.

<p>Survival of PT4 cells (A, E); MM1 cells (B) and FO-1 cells (C, D) after 6 days of treatment with the indicated substances and solvent controls. The medium renewal schedule was identical to that used for the cultures containing GBM TICs (see Introduction). Cell survival is expressed in arbitrary units as evaluated by MTT analysis. Standard deviations are indicated as vertical bars (n = 3 independent assays). DMSO concentration in (D) was 0.1% vol/vol. Drug concentrations in (D) were: NAC 20 mM, PLX4032 10 µM. Gefitinib final concentration in (E) was 3.9 µM. #The unpaired t-test was significant at P<0.05. §The unpaired t-test was significant at P = 0.01 or less. *The unpaired t-test was significant at P<0.001. **The unpaired t-test was significant at P<0.0001.</p

NAC, tiron and trolox determine only modest changes in the ROS levels in the PT4 cell culture containing GBM TICs.

<p>Representative experiment of FCM analysis of PT4 culture containing GBM TICs cells incubated with the indicated fluorescent probe after 48(containing NAC, tiron or trolox) replacement. DCFDA, MitoSOX Red and TMRE were used to evaluate global ROS, mitochondrial superoxide and mitochondrial proton gradient, respectively. This analysis showed that trolox reduced global cellular ROS levels but did not substantially modify mitochondrial superoxide levels. NAC and tiron, instead, slightly decreased mitochondrial superoxide levels while slightly enhancing global cellular ROS levels. This analysis also showed that the drugs used in this study did not induce changes of the mitochondrial proton gradient displayed by the PT4 cells in control conditions.</p

Cell cultures containing GBM TICs display higher endogenous ROS generation than normal astrocytes.

<p>Representative experiment of FCM analysis of normal human astrocytes (NA) and cell cultures containing GBM TICs obtained from four different patients (PT1, PT2, PT4, PT5) incubated with the indicated fluorescent probe. Mitotracker Green, TMRE, DCFDA and MitoSOX Red were used to evaluate mitochondrial mass, mitochondrial proton gradient, global ROS and mitochondrial superoxide, respectively.</p